Replies to post #3013 on BioCurex, Inc.(fka BOCX)

[Kag]

Gaboy,
It is my humble opinion that Abbott will delay forking over the first milestone payment to BioCurex as long as possible, especially if it is a sizable amount of money, since the first milestone payment seems to be based solely on Abbott's successful completion of its own internal feasibility review. The achievement of the first milestone sounds like something that Abbott has total control over. So it is also my opinion that Abbott will not announce the first milestone until something concerning the implementing of RECAF into their Architect system has to be placed in the public domain. That could be a lot of things including things that involve the FDA. I just think that the revenue generated from a RECAF blood screening test for cancer or as a follow up test for those patients who have been treated for cancer (to determine if the cancer is gone) could eventually be of blockbuster proportions. kag